MARKET

SPRB

SPRB

SPRUCE BIOSCIENCES, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.10
-0.60
-7.79%
After Hours: 7.10 0 0.00% 19:48 09/17 EDT
OPEN
7.73
PREV CLOSE
7.70
HIGH
7.73
LOW
6.87
VOLUME
157.45K
TURNOVER
--
52 WEEK HIGH
35.60
52 WEEK LOW
6.87
MARKET CAP
165.98M
P/E (TTM)
-4.0936
1D
5D
1M
3M
1Y
5Y
Spruce Biosciences to Participate in September Investor Conferences
SAN FRANCISCO, September 07, 2021--Spruce Biosciences to Participate in September Investor Conferences
Business Wire · 09/07 20:05
BRIEF-Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual Research And Development Day
reuters.com · 08/25 13:17
The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 12)
Benzinga · 08/13 11:43
Stocks That Hit 52-Week Lows On Thursday
    During Thursday's morning trading, 83 companies set new 52-week lows.
Benzinga · 08/12 14:06
The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11)
Benzinga · 08/12 12:09
Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary Syndrome
Late-stage biopharmaceutical company Spruce Biosciences Inc (NASDAQ: SRPB) reported financial results for the second quarter ended June 30, 2021 and announced that it has submitted an investigational new drug application (IND) for tildacerfont in the treat...
Benzinga · 08/11 12:55
BRIEF-Spruce Biosciences Reports Second Quarter 2021 Financial Results
reuters.com · 08/10 21:17
Spruce Biosciences Q2 EPS $(0.50) Up From $(8.43) YoY
Spruce Biosciences (NASDAQ:SPRB) reported quarterly losses of $(0.50) per share. This is a 94.07 percent increase over losses of $(8.43) per share from the same period last year.
Benzinga · 08/10 21:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SPRB. Analyze the recent business situations of SPRUCE BIOSCIENCES, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SPRB stock price target is 32.20 with a high estimate of 44.00 and a low estimate of 26.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 21.89M
% Owned: 93.63%
Shares Outstanding: 23.38M
TypeInstitutionsShares
Increased
17
453.40K
New
5
2.20M
Decreased
12
785.00K
Sold Out
4
641.75K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.49%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Executive Director/Director
Michael Grey
Chief Executive Officer/Director/Primary Contact
Richard King
Chief Financial Officer
Samir Gharib
Other
Rosh Dias
Director
Kirk Ways
Independent Director
Tiba Aynechi
Independent Director
Dina Chaya
Independent Director
Bali Muralidhar
Independent Director
Niall O'donnell
Independent Director
Camilla Simpson
Independent Director
Daniel Spiegelman
No Data
About SPRB
Spruce Biosciences, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for endocrine disorders. The Company's development product candidate, tildacerfont, is a non-steroidal therapy that offers disease control for patients suffering from congenital adrenal hyperplasia (CAH). Tildacerfont is a non-steroidal, oral antagonist of the corticotropin-releasing hormone receptor 1 (CRF1) receptor, which is the receptor for corticotropin-releasing factor (CRF). By blocking the CRF1 receptor, tildacerfont enables to address the uncontrolled cortisol feedback regulatory pathway in CAH and reduce the production of adrenocorticotropic hormone (ACTH) in the pituitary, limiting the amount of androgen produced downstream from the adrenal gland. Tildacerfont also enables treating physicians to lower the supraphysiologic glucocorticoid doses given to CAH patients to near physiologic levels.

Webull offers kinds of Spruce Biosciences Inc stock information, including NASDAQ:SPRB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SPRB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SPRB stock methods without spending real money on the virtual paper trading platform.